Twitter | Search | |
Search Refresh
Els Torreele Nov 21
I can’t believe we are still arguing with about whether we have a problem with too expensive medicines while the house is on fire
Reply Retweet Like
Yannis Natsis Nov 21
Such a critical question. Lets fix the orphan drugs regulation to discourage the abuse of the incentives & profiteering
Reply Retweet Like
Veselības projekti Nov 21
Most countries are not aware of how much they are overpaying for their medicines, Dr Andrew Hill,
Reply Retweet Like
EPHA Nov 21
Aldo Golja "We need an international consensus on sustainable innovation model. If you want more transparency, you also need more international cooperation."
Reply Retweet Like
EPHA Nov 21
"No one in this room is anti innovation. We welcome innovation -but we are anti abuse. Are incentives currently abused, misused or overused?"
Reply Retweet Like
Els Torreele Nov 21
Great start of for better and affordable medicines meeting by with Andrew Hill presenting
Reply Retweet Like
Yannis Natsis Nov 21
We should NEVER forget that IPR incentives are privileges NOT rights granted by governments to
Reply Retweet Like
Catta Nov 21
Regulators don't ask as much as they could when they approve . we need to empower them, says patient representative at
Reply Retweet Like
Emma Cracknell Nov 21
Since OMP adopted, 136 orphan meds have been approved versus 8 before. Incentives are delivering.
Reply Retweet Like
EPHA Nov 21
Dr Hill "Europe could save 30bln per year if transparency measures were in place"
Reply Retweet Like
Sabrina Wimmer Nov 21
"There is no useful innovation if it's not accessible" - Els Torreele
Reply Retweet Like
England Rugby Nov 16
Looking for ways to turn defence into attack? ⚡️ Give Interceptors a go in your next training training session 🙌
Reply Retweet Like
Elizabeth Kuiper Nov 21
Couldn’t agree more! We need to stop shouting at each other and start working together on new models for innovation, says
Reply Retweet Like
LillyPad EU Nov 21
To enable R&D in high unmet medical need diseases like ’s, a reliable system that incentivises investment into high risk research areas is key
Reply Retweet Like
Yannis Natsis Nov 21
I honestly don't think I have ever been to such a debate on in Bxl before like the current/final panel of
Reply Retweet Like
Charlotte Roffiaen Nov 21
Listening to Rainer Becker at I'm amazed that seems to do more for access to medicines than
Reply Retweet Like
EPHA Nov 21
"One of the main problems that prevent countries from being on target on curing is pricing!" says Dr Hill
Reply Retweet Like
Manuel Martin Nov 21
All elements of clinical trial transparency are implemented by at least one pharmaceutical company and they often do better than universities.
Reply Retweet Like
Sense about Science Nov 21
Here's audit of large global pharma companies' policies on clinical trial transparency published in
Reply Retweet Like
Yannis Natsis Nov 21
Andrew Hill says that so far Hep C has brought 67$bn in revenue for pharma
Reply Retweet Like